NCT03818503 E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
| NCT ID | NCT03818503 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2019-06-24 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2019-06-24 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed cancer. * Written informed consent for E²-RADIatE according to applicable legal and ethical requirements * Planned use of radiotherapy * Eligibility of the patient confirmed for at least one cohort confirmed * Patients of 12 years and older
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03818503 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03818503 currently recruiting?
Yes, NCT03818503 is actively recruiting participants. Contact the research team at 1811@eortc.org for enrollment information.
Where is the NCT03818503 trial being conducted?
This trial is being conducted at Graz, Austria, Linz, Austria, Vienna, Austria, Aalst, Belgium and 11 additional locations.
Who is sponsoring the NCT03818503 clinical trial?
NCT03818503 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.